96. クローン病 Crohn disease Clinical trials / Disease details
臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05197049 (ClinicalTrials.gov) | January 19, 2022 | 17/1/2022 | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Crohn's Disease | Crohn Disease | Drug: Guselkumab Dose 1;Drug: Guselkumab Dose 2;Drug: Guselkumab Dose 3;Drug: Placebo | Janssen Research & Development, LLC | NULL | Recruiting | 18 Years | N/A | All | 318 | Phase 3 | United States;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Lithuania;Malaysia;Netherlands;New Zealand;Norway;Poland;Serbia;Slovakia;Spain;Taiwan;Turkey;United Kingdom;Belarus;Bulgaria;Estonia;Finland;Mexico;Portugal;Russian Federation;Sweden;Ukraine |
| 2 | NCT03466411 (ClinicalTrials.gov) | April 13, 2018 | 8/3/2018 | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | Crohn's Disease | Drug: Guselkumab Dose 1;Drug: Guselkumab Dose 2;Drug: Guselkumab Dose 3;Drug: Guselkumab Dose 4;Drug: Guselkumab Dose 5;Drug: Guselkumab;Drug: Ustekinumab;Drug: Placebo | Janssen Research & Development, LLC | NULL | Active, not recruiting | 18 Years | N/A | All | 1409 | Phase 2/Phase 3 | Latvia;Lebanon;Lithuania;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;Chile;Ireland;Macedonia, The Former Yugoslav Republic of;Norway;Slovenia;South Africa;Sweden;Switzerland;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of |